Personalized cell therapy for childhood cancer
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new, personalized cell therapy for children with high-risk neuroblastoma or DIPG (a type of brain tumor) that has come back or is hard to treat. It uses the patient's own tumor to create a treatment that might work better for them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 30 years old or younger.
- You must have either high-risk neuroblastoma that has come back or not responded to treatment, or a type of brain tumor called DIPG that is newly diagnosed and you are willing to have a biopsy.
- You need to be in reasonably good health, with enough blood cell counts and good kidney and liver function.
- You must agree to a biopsy to get tumor material for the treatment.
- If you have brain involvement and are on steroids, the dose must be stable for at least a week before the biopsy.
- You must not have a serious infection or other major medical condition that could interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (CAR T-cells) that targets a protein called CD70 found on some brain tumor cells. It is for children and young adults with newly diagnosed or recurrent high-grade glioma, including DIPG.
This trial tests a personalized CAR-T cell therapy that targets three specific markers (GD2, PSMA, and CD276) on neuroblastoma cells. It is for patients whose cancer has come back or not responded to standard treatment.
This Phase 1 study tests lab-made donor immune cells (gamma delta T cells) plus chemotherapy to treat neuroblastoma or osteosarcoma that has come back or hasn’t responded to standard treatment. It’s designed to find a safe way to give this treatment and to see how well it might work.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This trial tests a new type of immune cell therapy called CAR T cells that are designed to recognize and attack cancer cells in children and young adults with certain solid tumors that have come back or not responded to standard treatment.
This trial tests a new CAR T cell therapy (BCB-276) for children and young adults with a type of brain tumor called DIPG. The therapy uses your own immune cells that are specially trained to attack the cancer.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.